Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,580.70 +125.86 1.01%
S&P 500 1,332.42 +14.60 1.11%
Nasdaq 2,870.99 +33.46 1.18%
Ticker Volume Price Price Delta
STOXX 50 2,160.31 +12.39 0.58%
FTSE 100 5,391.14 +34.80 0.65%
DAX 6,396.84 +73.65 1.16%
Ticker Volume Price Price Delta
Nikkei 8,657.08 +63.93 0.74%
TOPIX 727.03 +5.92 0.82%
Hang Seng 19,055.50 +254.47 1.35%
Gold 1,555.00 +0.26%
EUR-USD 1.2481 -0.1762%
Nasdaq 2,870.99 +1.18%
DJIA 12,580.70 +1.01%
S&P 500 1,332.42 +1.11%
FTSE 100 5,391.14 +0.65%
STOXX 50 2,160.31 +0.58%
DAX 6,396.84 +1.16%
Oil (WTI) 90.76 0.00%
U.S. 10-year 1.745% +0.007
BAC:US 7.44 +4.06%
FB:US 28.84 -9.62%
  • Exchange: NASDAQ GM
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

XOMA Corp

Add to Portfolio

XOMA:US

2.5000 USD 0.1200 5.04%

As of 17:20:00 ET on 05/29/2012.

Snapshot for XOMA Corp (XOMA)

Open: 2.3500 Day's Range: 2.3401 - 2.5300 Volume: 804,238 Bid: 2.4800
Previous Close: 2.3800 52wk Range: 1.0400 - 3.1400 1-Yr Rtn: -17.49% Ask: 2.5000

Stock Chart for XOMA

No chart data available.
  • XOMA:US 2.5000
  • 1D
  • 1M
  • 1Y
2.3800
Interactive XOMA Chart

Previous Close

Key Statistics for XOMA

Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share (USD) (ttm) -1.0300
Est. EPS (USD) (12/2012) -1.1700
Est. PEG Ratio -
Market Cap (M USD) 170.21
Shares Outstanding (M) 68.08
Enterprise Value (M USD) (ttm) 131.69
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 8.7331
Price/Sale (ttm) 1.6059
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/03/2012
More XOMA Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for XOMA

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)
More XOMA Income Statement Data
  • Total Assets
  • Total Liabilities (M/USD)
  • Debt to Assets (%)
More XOMA Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/USD)
More XOMA Cash Flow Data

Company Profile & Key Executives for XOMA

XOMA Corporation is a biopharmaceutical company that develops and manufactures genetically engineered protein, peptide, and antibody pharmaceuticals. The Company's medical targets include bacterial and fungal infections, infectious complications, and immunologic and inflammatory disorders. XOMA's primary drug development platform is bactericidal/permeability-increasing protein.

W Denman Van NessChairmanJohn VarianChief Executive Officer
Patrick J ScannonExec VP/Chief Scientific OfcrFred KurlandVP:Finance/CFO
More Company Profile & Key Executives for XOMA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements